Schroder Investment Management Group Sells 166,152 Shares of Masimo Co. (NASDAQ:MASI)

Schroder Investment Management Group trimmed its stake in shares of Masimo Co. (NASDAQ:MASI) by 22.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 566,469 shares of the medical equipment provider’s stock after selling 166,152 shares during the quarter. Schroder Investment Management Group owned approximately 1.06% of Masimo worth $95,501,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. raised its holdings in Masimo by 1.5% during the 4th quarter. Vanguard Group Inc. now owns 4,586,702 shares of the medical equipment provider’s stock valued at $758,182,000 after buying an additional 66,215 shares during the last quarter. State Street Corp raised its stake in shares of Masimo by 0.7% during the third quarter. State Street Corp now owns 1,438,814 shares of the medical equipment provider’s stock valued at $191,837,000 after acquiring an additional 10,179 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Masimo by 1.5% in the third quarter. Geode Capital Management LLC now owns 792,886 shares of the medical equipment provider’s stock worth $105,741,000 after purchasing an additional 11,984 shares during the last quarter. Charles Schwab Investment Management Inc. grew its stake in shares of Masimo by 2.1% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 377,836 shares of the medical equipment provider’s stock worth $62,456,000 after purchasing an additional 7,808 shares during the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. increased its holdings in Masimo by 0.4% during the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 373,705 shares of the medical equipment provider’s stock valued at $61,773,000 after purchasing an additional 1,522 shares during the period. Institutional investors own 85.96% of the company’s stock.

Insider Buying and Selling at Masimo

In other Masimo news, Director Craig B. Reynolds sold 2,053 shares of the business’s stock in a transaction dated Friday, March 14th. The stock was sold at an average price of $166.13, for a total value of $341,064.89. Following the completion of the transaction, the director now owns 16,581 shares of the company’s stock, valued at approximately $2,754,601.53. The trade was a 11.02 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Bilal Muhsin sold 30,000 shares of the firm’s stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $167.49, for a total transaction of $5,024,700.00. Following the sale, the chief operating officer now directly owns 24,172 shares in the company, valued at approximately $4,048,568.28. The trade was a 55.38 % decrease in their position. The disclosure for this sale can be found here. 9.70% of the stock is owned by company insiders.

Masimo Price Performance

MASI opened at $163.55 on Monday. Masimo Co. has a 12-month low of $101.61 and a 12-month high of $194.88. The company has a market cap of $8.82 billion, a price-to-earnings ratio of 112.79 and a beta of 1.04. The company has a current ratio of 2.01, a quick ratio of 1.11 and a debt-to-equity ratio of 0.50. The stock has a fifty day simple moving average of $174.79 and a two-hundred day simple moving average of $161.72.

Masimo (NASDAQ:MASI) last issued its quarterly earnings results on Tuesday, February 25th. The medical equipment provider reported $1.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.42 by $0.38. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The company had revenue of $600.70 million during the quarter, compared to analyst estimates of $593.35 million. Research analysts predict that Masimo Co. will post 4.1 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. Needham & Company LLC reiterated a “hold” rating on shares of Masimo in a research report on Wednesday, February 26th. Raymond James boosted their price objective on shares of Masimo from $170.00 to $194.00 and gave the company an “outperform” rating in a research report on Friday, December 27th. Wells Fargo & Company raised their target price on shares of Masimo from $193.00 to $205.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 26th. Finally, Piper Sandler lifted their target price on shares of Masimo from $210.00 to $215.00 and gave the company an “overweight” rating in a research note on Wednesday, February 26th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, Masimo presently has an average rating of “Moderate Buy” and an average target price of $194.80.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.